

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|                      |   |                  |        |
|----------------------|---|------------------|--------|
| Application No.      | : 10/687,913  | Confirmation No. | : 2270 |
| First Named Inventor | : Wank, Rudolf  |                  |        |
| Filed                | : October 20, 2003  |                  |        |
| TC/A.U.              | : 1644  |                  |        |
| Examiner             | : Zachary S. Skelding   |                  |        |
| Docket No.           | : 104341.B090019  |                  |        |
| Title                | : Use of Stimulated Peripheral-Blood Mononuclear Cells for<br>the Treatment of Cancerous Diseases |                  |        |

**RENEWED REQUEST FOR CERTIFICATE OF  
CORRECTION UNDER 37 C.F.R. § 1.323**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

It is respectfully requested that the attached Certificate of Correction be entered in the patent identified above. It is noted that the 35 U.S.C. § 120 priority was incorrectly referenced as required by 37 C.F.R. § 1.78(a)(2). A Renewed Petition under 37 C.F.R. § 1.78 is attached.

Pursuant to M.P.E.P. § 1481.03, Applicants respectfully state that the following requirements for correcting priority under 35 U.S.C. § 120 as based on an international application via a Certificate of Correction are satisfied.

(A) All requirements set forth in 37 C.F.R. § 1.78(a)(1) have been met

- i. The inventor is the same in the later-filed application, and the inventor's invention is claimed in at least one claim of the later-filed application
- ii. The international application is entitled to a filing date in accordance with PCT Article 11
- iii. The international application designates the United States of America

(B) It is clear from the record of the patent and parent applications that the priority is appropriate. The record shows that this application is a continuation of PCT/EP02/04524, filed on April 24, 2002, which claims priority to German application no. 101 20 505, filed April 26, 2001. As

support for this statement, Applicants point to the acknowledgement made by the Examiner in the Office Action mailed March 3, 2010. The Examiner stated "the claim to the benefit of priority of the filing date of DE 101 20 505.8 put forth in this application is valid", thereby implicitly stating that the priority claim to the international application, which links the present application to the German application, is also valid.


(C) Copies of documentation showing designation of states is enclosed, which makes it clear that 35 U.S.C. § 120 priority for a continuation application is appropriate

(D) A renewed petition to accept an unintentionally delayed claim for the benefit of a prior application, is being filed concurrently herewith.

The required fee under 37 C.F.R. § 1.20(a) in the amount of \$100.00 is believed to have been paid previously, but if any additional fee is required for this request, please charge such fee to the Deposit Account No. 05-1323, Docket No. 104341.B090019.

Respectfully submitted,

May 19, 2011

  
\_\_\_\_\_  
Deborah H. Yellin  
Registration No. 45,904

CROWELL & MORING LLP  
Intellectual Property Group  
P.O. Box 14300  
Washington, DC 20044-4300  
Telephone No.: (202) 624-2500  
Facsimile No.: (202) 628-8844  
DHY:SML

(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES  
PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG

(19) Weltorganisation für geistiges Eigentum  
Internationales Büro



(43) Internationales Veröffentlichungsdatum  
7. November 2002 (07.11.2002)

PCT

(10) Internationale Veröffentlichungsnummer  
**WO 02/087612 A2**

(51) Internationale Patentklassifikation<sup>7</sup>: **A61K 39/00**,  
35/14, A61P 35/00

(21) Internationales Aktenzeichen: PCT/EP02/04524

(22) Internationales Anmeldedatum:  
24. April 2002 (24.04.2002)

(25) Einreichungssprache: Deutsch

(26) Veröffentlichungssprache: Deutsch

(30) Angaben zur Priorität:  
101 20 505.8 26. April 2001 (26.04.2001) DE

(71) Anmelder und

(72) Erfinder: WANK, Rudolf [DE/DE]; Hans-Sachs-Strasse  
12, 80469 München (DE).

(74) Anwalt: WIBBELMANN, Jobst; Wuesthoff &  
Wuesthoff, Patent- und Rechtsanwälte, Schweiger-  
strasse 2, 81541 München (DE).

(81) Bestimmungsstaaten (national): AE, AG, AL, AM, AT,  
AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR,

CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE,  
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU,  
SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,  
US, UZ, VN, YU, ZA, ZM, ZW.

(84) Bestimmungsstaaten (regional): ARIPO-Patent (GH,  
GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW),  
eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ,  
TM), europäisches Patent (AT, BE, CH, CY, DE, DK,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR),  
OAPI-Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).

Veröffentlicht:

— ohne internationalen Recherchenbericht und erneut zu  
veröffentlichen nach Erhalt des Berichts

Zur Erklärung der Zweibuchstaben-Codes und der anderen  
Abkürzungen wird auf die Erklärungen ("Guidance Notes on  
Codes and Abbreviations") am Anfang jeder regulären Ausgabe  
der PCT-Gazette verwiesen.

WO 02/087612 A2

(54) Title: USE OF STIMULATED PERIPHERAL BLOOD MONONUCLEAR CELLS FOR TREATING CANCEROUS DIS-  
EASES

(54) Bezeichnung: VERWENDUNG VON STIMULIERTEN MONONUKLEÄREN ZELLEN DES PERIPHEREN BLUTES  
ZUR BEHANDLUNG VON KREBSERKRANKUNGEN

(57) Abstract: The invention relates to the use of peripheral blood mononuclear cells that have been stimulated by means of cascade  
memory imprinting (cascade primed (CAPRI) cells) for providing an agent for treating cancerous diseases. The CAPRI cells can  
also be administered in combination with CD3-activated cells.

(57) Zusammenfassung: Die Erfindung betrifft die Verwendung von über eine Kaskaden-Gedächtnisprägung stimulierten mono-  
nukleären Zellen des peripheren Blutes (CAPRI-Zellen) zur Bereitstellung eines Mittels zur Behandlung von Krebserkrankungen.  
Die CAPRI-Zellen können auch in Kombination mit CD3-aktivierten Zellen verabreicht werden.